Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06985290

Dexmedetomidine Versus Morphine During Cooling Therapy in Neonates

About ~3/ 1000 live-born newborns may suffer from brain injury due to a transient drop in oxygen supply to the brain during the birth process. The degree of brain injury that ensues in the first 72 hours after the injury is directly proportional to the severity of long-term childhood disabilities (e.g., cerebral palsy and developmental delays). Whole-body cooling during the first 3 days of life is proven effective in reducing the severity of brain injury. However, cooling therapy leads to pain, shivering, stress, and discomfort. The best way to alleviate the pain and agitation of cooled newborns is unknown. Standard practice is to provide morphine infusion to reduce pain. Recently, a new drug called "dexmedetomidine" has been tested in small studies and has been found to be safe during cooling in newborns. Dexmedetomidine has added beneficial effects such as anti-inflammation, faster recovery, and shorter hospital stays. This study is going to test the feasibility of conducting a future clinical trial to compare the effects of using Dexmedetomidine versus morphine in the management of cooling-related pain/agitation on the severity of brain injury in the first week of life. The study will also examine the effect of dexmedetomidine compared to morphine on short-term clinical outcomes, parental experiences and developmental outcomes at 1 year.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Gestational age >= 35 weeks
  • Birth weight >= 2500g
  • Sign of perinatal hypoxic event (any of the following): (a) Arterial Cord blood gas or postnatal gas within 1 hour of life pH <= 7.00 OR Base Deficit >= 16 (b) Arterial Cord blood gas postnatal gas within 1 hour of life pH 7.00 -7.15 AND Acute sentinel intrapartum event
  • Sign of Neonatal Encephalopathy
  • Initiation of Therapeutic Hypothermia within 8 hours of life

Exclusion criteria

  • Informed consent not obtained within 20 hours of life
  • Congenital Brain Malformations (antenatally known)
  • Major Chromosomal Anomaly (antenatally diagnosed)
  • Congenital neuromuscular disorder

Treatment and study plan

Dexmedetomidine infusion

Drug

Dexmedetomidine infusion given for sedation during therapeutic hypothermia. Dexmedetomidine infusion at a starting dose of 0.2 μg/kg/h, with titration in 0.1 μg/kg/h increments with a maximum of 0.5 μg/kg/h based on objective assessment of sedation.

Morphine Infusion

Drug

Morphine infusion given for sedation during therapeutic hypothermia. Morphine infusion at a starting dose of 4 μg/kg/h, with titration in 2 μg/kg/h increments with a maximum of 10 μg/kg/h based on objective assessment of sedation.

Primary outcomes

  1. Recruitment Rate

    Time frame: Day 1

    Proportion of eligible neonates enrolled. Calculation = (Number of neonates enrolled) X 100/(Total eligible neonates)

  2. Follow Up Rate

    Time frame: From enrollment to 1 year of age

    Percentage of neonates completing the study. Calculation = (Neonates who completed the study) x 100/ (Total neonates consented)

  3. Adverse Event Rate

    Time frame: From enrollment to 7 days of life

    Incidence of adverse events Measurement of Adverse Event Rate = (Number of neonates experiencing) x100/ (Total neonates exposed to the intervention)

  4. Discontinuation Rate

    Time frame: From enrollment to 7 days of life

    Need for intervention discontinuation due to adverse effects. Measurement of Discontinuation Rate = (Number of neonates for whom the intervention discontinued) x 100/ (Total neonates consented)

  5. Protocol Adherence Rate

    Time frame: through study completion, average 1 year

    Percentage of correct drug adjustment based on changes in COMFORTneo scale as per protocol. Calculation of Drug Administration Compliance = (Number of correctly administered medication per month) x 100/ (Total number of participant enrolled per month)

Secondary outcomes

  1. Severity of Brain Injury on Magnetic Resonance Imaging (MRI)

    Time frame: From enrollment to 10 days of life

    The T1 and T2 weighted images, diffusion-weighted images, and magnetic resonance spectroscopy (MRS) are additionally evaluated to determine the level of brain damage. MRI scoring system reported by Weeke et al. will be used to classify brain injury based on 4 subscores, including grey matter (basal ganglia, thalamus, PLIC, brainstem, perirolandic cortex, and hippocampus), white matter/cortex (including optic radiation and corpus callosum), and cerebellum.

  2. Seizure Burden during Therapeutic Hypothermia

    Time frame: From enrollment to 72 hours of life

    Total duration of seizures noted during the first 72 hours of life

  3. Stress levels measured by Salivary cortisol assay at 24 and 48 hours

    Time frame: From enrollment to 48 hours of life

    Salivary cortisol levels will be used as an objective marker of neonatal stress measured in µg/dL.

  4. Neonatal Sedation and Discomfort Levels

    Time frame: From enrollment to 4 days of life

    COMFORT neo scores during the period of therapeutic hypothermia. It consists of 7 behavioural items (alertness, calmness/agitation, respiratory response, crying, body movement, facial tension and muscle tone), of which six items should be scored (respiratory response or crying depends on the presence of invasive ventilation). The neonate will be observed for 2 minutes to score. Total scores range from 7 to 35. A score >14 is considered a sign of distress and undersedation. A score < 9 suggests oversedation.

  5. Time to Reach Full Oral Feeds

    Time frame: up to 4 weeks of life

    Days of life when participant is receiving all oral feeds either breast or bottle

  6. Cumulative dose of PRN opioid boluses given during therapeutic hypothermia

    Time frame: up to 4 days of life

    Total dose of morphine and fentanyl given during therapeutic hypothermia measured in mg/kg of morphine equivalent

  7. Length of Hospital Stay

    Time frame: up to 4 weeks of life

    Day of life when discharged home

  8. Days on invasive and non-invasive respiratory support

    Time frame: Up to 4 weeks of life

    Day of life when comes off all respiratory support to room air

Other outcomes

  1. Parental Stress Index

    Time frame: Up to 4 weeks of life

    Parental Stress Index - Short Form (PSI-SF) will be administered to parents of study subjects at discharge from NICU to compare stress levels between neonates of the two groups. The short form is derived from the original Parental Stress Index (PSI). It consists of 36 items across three subscales namely (i) Parental Distress (PD): stress related to personal factors (e.g., depression, lack of support), (ii) Parent-Child Dysfunctional Interaction (P-CDI): stress about the child not meeting expectations and (iii) Difficult Child (DC): stress due to child's behavioral difficulties. Each item is rated 1 (Strongly Disagree) to 5 (Strongly Agree). Percentiles based on normative data are used to interpret scores.

    >85th percentile indicates clinically significant stress, 90th-99th percentile indicates highly elevated stress.

  2. Parental Experiences

    Time frame: From discharge to 4 weeks post-discharge

    Parental experiences captured through semi-structured interviews will be audio-recorded and transcribed.

  3. Developmental Outcomes at 12 months

    Time frame: Between 10-14 months of enrollment

    Ages and Stages Questionnaire-3rd edition (ASQ-3) to assess five areas of childhood development: Communication, Gross motor, Fine motor, Problem-solving, and Personal-social through parent/caregiver reports. Each item is answered as Yes (10 points), Sometimes (5 points) and Not Yet (0 points).

    Each domain has 6 questions, hence a maximum 60 points per domain. After summing scores for each domain, total score is interpretated as: (i) Above Cutoff (Development is on schedule), (ii) Close to Cutoff (within 1 SD) (Monitor, Child may need re-screening soon) and (iii) Below Cutoff (Referral to specialist for further evaluation recommended).

Study contacts

Contact information is provided by the study sponsor or research team.

IPSITA GOSWAMI, MD

CONTACT

[email protected]

9055212100

Sponsors and collaborators

Lead sponsor

Ipsita Goswami

Other

Registry information

Official study title

Comparative Efficacy of Dexmedetomidine Versus Morphine in Alleviating Secondary Brain Injury, When Used for Sedation During Hypothermia Therapy in Neonates: A Pilot Randomized Trial

Acronym: COOL-SED

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
May 22, 2025
Registry last updated
May 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.